Abbreviations
- 1-MT:
-
1-Methyl tryptophan
- AML:
-
Acute myeloid leukemia
- ACT:
-
Adoptive cell therapy
- AEs:
-
Adverse events
- Haplo-HSCT:
-
Haploidentical hematopoietic stem cell transplantation
- APC:
-
Antigen-presenting cells
- APM:
-
Antigen processing and presentation machinery
- B-NHLs:
-
B cell non-Hodgkin lymphoma
- BLI:
-
Bioluminescence imaging
- BM:
-
Bone marrow
- CIC:
-
Cancer initiating cells
- CSC:
-
Cancer stem cells
- CTA:
-
Cancer–testis antigen
- CEA:
-
Carcinoembryonic antigen
- CCL:
-
Chemokine (C–C motif) ligand
- CAR:
-
Chimeric antigen receptors
- CLL:
-
Chronic lymphocytic leukemia
- CRC:
-
Colorectal cancer cells
- CREB:
-
cAMP response element-binding protein
- CIK:
-
Cytokine-induced killer
- CTLA-4:
-
Cytotoxic T-lymphocyte antigen 4
- DC:
-
Dendritic cells
- T-bodies:
-
Engineered T cells
- EAP:
-
Expanded access program
- GVHD:
-
Graft versus host disease
- VH CDR3:
-
Heavy complementarity-determining region 3
- HLA:
-
Human leukocyte antigen
- hPSMA:
-
Human prostate-specific membrane antigen
- HAS:
-
Human serum albumin
- Ig:
-
Immunoglobulin
- IDO:
-
Indoleamine 2,3-dioxygenase
- isoDGR:
-
IsoAsp-Gly-Arg
- KIR:
-
Killer cell immunoglobulin-like receptor
- LAG-3:
-
Lymphocyte activation gene-3
- LN:
-
Lymph node
- MHC:
-
Major histocompatibility complex
- MC:
-
Mast cells
- MMP-9:
-
Metalloproteinase-9
- mAb:
-
Monoclonal antibody
- MM:
-
Multiple myeloma
- MDSC:
-
Myeloid-derived suppressor cells
- NK:
-
Natural killer
- NSCLC:
-
Non-small-cell lung cancer
- OS:
-
Overall survival
- PBMC:
-
Peripheral blood mononuclear cell
- PD-1:
-
Programmed cell death-1
- PD-L1:
-
Programmed cell death-1 ligand 1
- TGF:
-
Transforming growth factor
- TRAMP:
-
Transgenic adenocarcinoma of the mouse prostate
- TAA:
-
Tumor-associated antigen
- TNF-alpha:
-
Tumor necrosis factor alpha
- TCR:
-
T cell receptor
- Treg:
-
Regulatory T cells
- CD44v6:
-
Variant 6 of the adhesion receptor CD44
- VEGF:
-
Vascular endothelial growth factor
Acknowledgments
This work was supported in part by grants from: Associazione Italiana per la Ricerca sul Cancro (Hugues Jean Marie Nicolay fellow) and Istituto Toscano Tumori. A special thanks to the NIBIT members and meeting speakers for their contribution to the manuscript and the conference.
Conflict of interest
The authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was conducted on behalf of Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy.
Rights and permissions
About this article
Cite this article
Maio, M., Nicolay, H.J.M., Ascierto, P.A. et al. Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5–7, 2012. Cancer Immunol Immunother 62, 1851–1858 (2013). https://doi.org/10.1007/s00262-013-1496-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00262-013-1496-5